If we look at this in the context of other drug trials for hospitalized COVID-19 patients that got stopped early due to futility (i.e. Eli Lilly, Regeneron), this announcement is quite significant.
And if we look at the list of drugs/treatments that have been approved:
- remdesivir = questionable benefit
- convalescent plasma = FDA's stuff-up
- hydroxychloroquine = Gone with the Trumpet
It makes sense that the trial is allowed to continue its course. We don't want to have another case like the above. Given more data the trial may give us more understanding of the drug's effectiveness, for example it may identify a specific group where the drug work best (such as people over 60 etc.).
If we look at this in the context of other drug trials for...
-
- There are more pages in this discussion • 260 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |